ReviewJTO clinical and research reports2026
Safety Evaluation of Tarlatamab in SCLC: A Systematic Review and Meta-Analysis.
Review in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Tarlatamab, a bispecific T-cell engager targeting delta-like ligand 3 and CD3, demonstrated clinical activity both in previously treated SCLC and as intensification of maintenance immunotherapy. Owing to its action mechanism, tarlatamab exerts a new toxicity profile, needing careful management. Based on these premises, we performed a systematic review and meta-analysis to evaluate treatment-related adverse events (TRAEs) among available clinical trials enrolling patients with SCLC receiving tarlatamab monotherapy. Methods: The research protocol was recorded in PROSPERO register with ID no. 1163787. We included the following keywords: phase I, phase II, phase III, small cell lung cancer, and tarlatamab. We conducted research in Embase, PubMed, Scopus, and Web of Science databases. Results: A total of four studies with 457 observations were included. Although Egger's test was performed, the results must be interpreted with caution as the small number of included studies ( Conclusions: Future research should be focused on identifying risk factors for TRAEs and developing prophylactic strategies to mitigate this risk without blunting antitumor efficacy in patients with SCLC receiving tarlatamab. By improving our understanding and management of tarlatamab TRAEs, we can maximize its clinical efficacy while minimizing harm and ultimately improving outcomes for patients with SCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.